A Phase 2a Study to Evaluate The Clinical Efficacy of JNJ-42756493, A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Patients With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Gastric Cancer, Esophageal Cancer Or Cholangiocarcinoma
Phase of Trial: Phase II
Latest Information Update: 26 Jan 2018
At a glance
- Drugs Erdafitinib (Primary)
- Indications Cholangiocarcinoma; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Urogenital cancer
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 17 Aug 2017 Planned number of patients changed from 75 to 55.
- 17 Aug 2017 Planned End Date changed from 31 Dec 2019 to 31 Dec 2018.
- 31 Mar 2017 Planned End Date changed from 1 Aug 2019 to 31 Dec 2019.